Startseite>>Lipids>> Fatty Acids>>10-Nitrolinoleate

10-Nitrolinoleate (Synonyms: 10-LNO2, 10nitro9,12Octadecadienoic Acid, 10-NO2-LA)

Katalog-Nr.GC41867

10-Nitrolinoleat ist ein potenter Peroxisom-Proliferator-aktivierter Rezeptor γ (PPARγ) Agonist.

Products are for research use only. Not for human use. We do not sell to patients.

10-Nitrolinoleate Chemische Struktur

Cas No.: 774603-04-2

Größe Preis Lagerbestand Menge
100μg
66,00 $
Auf Lager
500μg
294,00 $
Auf Lager
1mg
521,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

10-Nitrolinoleate is the product of nitration of linoleate by NO-derived reactive species. Other nitrolinoleates detected in human plasma and urine include 9-, 12-, and 13-nitrolinoleate. Nitrolinoleates activate peroxisome proliferator-activated receptor γ (PPARγ; Ki = 133 nM), inducing CD36 expression in macrophages, adipocyte differentiation, and glucose uptake. Nitrolinoleates can also be metabolized by smooth muscle cells to produce nitrite derivatives which in turn form NO, leading to increased cGMP production and smooth muscle relaxation. Through the same mechanism, nitrolinoleate-derived NO suppresses leukocyte adhesion, in part through nitrosation of CD40. Alteratively, nitrolinoleates can act independently of NO/cGMP and PPARγ signaling to suppress neutrophil and macrophage functions.

Bewertungen

Review for 10-Nitrolinoleate

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 10-Nitrolinoleate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.